THERAPY DOSSIER · th-59e9e2786c92

MicroRNA-155 inhibitor (anti-miR-155)

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28682732 ↗2017Reported benefit

MicroRNA-155 Inhibition Promoted Wound Healing in Diabetic Rats.

RatWoundSprague-DawleyMaleTopical application to the wound

Model: Cutaneous excisional wound in streptozotocin-induced diabetic rats

Topical miR-155 inhibitor lowered miR-155 expression and accelerated cutaneous wound healing relative to PBS-treated diabetic and normal glucose groups, with fewer neutrophils and macrophages and greater CD31, collagen 1, TGF-beta1 and alpha-SMA.

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…